İstanbul MedChem Logo

Patented Molecule Request

Request access to Prof. Durdağı's patented therapeutic compound

BAU-243 Molecule Structure
Novel BH3 mimetic Bcl-2 inhibitor | Patent by Prof. Serdar Durdağı
BAU-243 Molecule Structure

⚠️ NOT FOR HUMAN USE - LABORATORY USE ONLY

Compound Identifiers

BAU-243 (BAU243, AN-698/40780701)

Physicochemical Properties

  • Molecular Weight: 501.60 Da
  • Formula: C₂₈H₂₇N₃O₄S
  • Solubility: 10 mM in DMSO

Available Quantities

  • 1 mg
  • 5 mg
  • 10 mg
Submit Request
Fill out the form to request this molecule for research purposes
About BAU-243

BAU-243 is a novel BH3 mimetic Bcl-2 inhibitor with high binding affinity that effectively reduces glioblastoma multiforme (GBM) cell proliferation, including cancer-initiating stem cell subpopulations. This compound represents a breakthrough in targeting tumor-initiating cells that are often resistant to conventional therapies.

Key Mechanisms
  • • Disrupts Beclin 1 and Bcl-2 interaction to activate autophagy
  • • Induces autophagic cell death regardless of Bcl-2 expression levels
  • • Promotes cell cycle arrest in low Bcl-2 expressing cells
  • • Targets critical residues involved in Beclin 1 BH3 domain binding
Biological Activity Highlights

In Vitro Activity

  • • IC₅₀ = 18.2 μM against A172 GBM cells and tumor-initiating stem cells
  • • Demonstrates significant anti-proliferative effects in both high and low Bcl-2 expressing cell lines
  • • Targets cancer stem-like cells that represent true tumor-initiating populations
  • • Shows minimal apoptosis induction while promoting autophagic cell death

In Vivo Efficacy

  • • 25 mg/kg dosage effectively reduces tumor growth in animal models
  • • Requires lower dosing compared to other BH3 mimetics (e.g., ABT-263 at 75 mg/kg)
  • • Demonstrates superior therapeutic window with reduced dosing requirements
  • • Maintains efficacy against treatment-resistant GBM stem cell populations

Important Information

  • • This molecule is covered by patent protection
  • • For laboratory research use only - not for human or veterinary use
  • • Requests are reviewed on a case-by-case basis for legitimate research purposes
  • • Material transfer agreements (MTA) may be required
  • • Response time is typically 3-5 business days
  • • For commercial inquiries or licensing opportunities, please contact us separately